Gastroenterology

Clinical Neuroscience

SEPTEMBER 30, 2023

[Sumatriptan-naproxen sodium fix-dose combination for acute migraine treatment, a review]

TAJTI János, CSÁTI Anett, SZOK Délia

[Migraine as a common primary headache disorder has a significant negative effect on quality of life of the patients. Its pharmacotreatment includes acute and preventative therapies. Based on the shared therapeutic guideline of the European Headache Federation and the European Academy of Neurology for acute migraine treatment a combination of triptans and non-steroidal anti-inflammatory drugs is recommended for acute migraine treatment in triptan-nonresponders. In this short review we summarized the results of the randomized controlled clinical trials evaluating the effectiveness and safety of sumatriptan (85 mg)/naproxen sodium (500 mg) fix-dose combination. It was revealed that the fix-dose combination was better than placebo for the primary outcomes of exemption of pain and headache relief at 2 hours. Furthermore the combination showed beneficial effect on accompanying symptoms of migraine attack (i.e. nausea, photo- and phonophobia). Adverse events were mild or moderate in severity and rarely led to withdrawal of the drug.
It can be concluded that sumatriptan (85 mg)/naproxen sodium (500 mg) fix-dose combination is effective, safe and well-tolerated in the acute treatment of migraine. ]

HUN 2023;76(9-10)

Clinical Neuroscience

SEPTEMBER 30, 2023

[Assessment of compliance and patient pathway among multiple sclerosis patients on disease modifying treatment]

MÁTYÁS Klotild, BOBÁL Tamás, ABONYI Zsolt

[Epidemiological data and the number of patients treated suggest that the proportion of Hungarian patients with Multiple Sclerosis (MS) receiving disease-modifying therapy (DMT) is lower than in some neighboring countries. We investigated possible reasons for this.

First we analysed patient compliance based on an anonymised database of the National Health Insurance Fund (NHIF). A total of 5441 patients were included in the analysis from NHIF prescription data from 1 July 2014 to 28 February 2021. In the second part of the study, a quantitative and qualitative assessment of patient journeys of MS patients was conducted. 

The compliance of Hungarian MS patients is good compared to international MS treatment data and outstanding compared to other neurological and other diseases, e.g. cardiovascular. This cannot be said about the results of the patient pathway analysis based on patient interviews. Patients indicated that they often have difficulty accessing public health care. Tracing their pathways revealed that they needed to see 3-5 doctors (general practitioner, various specialists) before a diagnosis was made. However, they gave positive feedback about MS Centres. They trusted their doctors, found them empathetic, but they would have liked more time to discuss lifestyle issues.

Compared to some neighbou­ring countries, Hungary has a lower proportion of patients with treated MS, which, given the good compliance of patients, highlights the problem of patient path in Hungary. Further training of fellow physicians is also a task for neurologists specialising in MS. Just as the most common symptoms of stroke have been successfully introduced into the public consciousness, the same can be the aim for MS.]

HUN 2023;76(9-10)

Clinical Neuroscience

SEPTEMBER 30, 2023

Efficacy of intravenous alpha lipoic acid in the treatment of neuropatic pain due to carpal tunnel syndrome

GÜLSAH ÖZTÜRK, BEKIR Enes DEMIRYUREK

In this study, we analyzed the effect of oral and oral + intravenous Alpha-lipoic acid (ALA) treatment on pain level and physical examination findings in patients diagnosed with carpal tunnel syndrome (CTS). A total of 115 patients patricipa­ted in the study. 40 patients were treated with oral ALA after iv. ALA the¬rapy, 35 patients received only oral ALA treatment and 40 patients did not receive any medication.

ENG 2023;76(9-10)

Clinical Neuroscience

SEPTEMBER 30, 2023

Neurobehavioral impairments in ciprofloxacin- treated osteoarthritic adult rats

KÉKESI Gabriella , DUCZA Eszter , GÁLITY Hristifor , BÜKI Alexandra , TÓTH Kálmán , TUBOLY Gábor , HORVÁTH Gyöngyi

Ciprofloxacin (CIP) is a broad-spectrum antibiotic widely used in clinical practice to treat musculoskeletal infections. Fluoroquinolone-induced neurotoxic adverse events have been reported in a few case reports, all the preclinical studies on its neuropsychiatric side effects involved only healthy animals. This study firstly investigated the behavioral effects of CIP in an osteoarthritis rat model with joint destruction and pain.

ENG 2023;76(9-10)

Clinical Neuroscience

SEPTEMBER 30, 2023

Prognostic value of indoleamine 2, 3-dioxygenase-1 expression in glial tumors

KAYA Munir , AKSOY Asude , ARTAS Gokhan , KAPLAN Metin

Gliomas are the most common primary malignant central nervous system tumors in adults, exhibiting a poor prognosis. Indoleamine 2, 3-dioxygenase-1 has important functions in cancer immunotherapy due to its role in escaping cancer cells from the immune system. In this study we purposed to evaluate the correlation between IDO-1 expression and clinicopathological parameters in gliomas, and whether IDO-1 can be a prognostic marker.

ENG 2023;76(9-10)

Lege Artis Medicinae

SEPTEMBER 30, 2023

[The practice of periprocedural anticoagulation – birth of a local consensus]

BENCZÚR Béla, RODEK Gyula, SIMON János

[The problem of periprocedural anticoa­gulation is emerging more and more frequently in the day-to-day patient care. There is fundamental the interdisciplinary approach spanning the borders of different specialties by establishing the “anticoagulant team” including specialists as cardiologist, anesthesiologist and surgical experts for hands-on interventions (surgeon, traumatologist, obstetrician, endoscopic spe­cialist etc.) and even the GPs as well. Such a communication can help considerably in the patient management and it would be useful to define local protocols and consensus papers adapted for the concerning hospitals. This review provides an overview of the points of considerations, the proposed practice of interruption and re-ad­ministration of oral anticuagulants, and the treatment of bleedings. ]

HUN 2023;33(8-9)